Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter

1992 ◽  
Vol 69 (4) ◽  
pp. 417-419 ◽  
Author(s):  
Maarten J. Suttorp ◽  
Peter E. Polak ◽  
Arnoud van't Hof ◽  
Henrik S. Rasmussen ◽  
Peter H. Dunselman ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Atrial Flutter ◽  
Paroxysmal Atrial Fibrillation ◽  
Antiarrhythmic Agent ◽  
Efficacy And Safety ◽  
Class Iii ◽  
Class Iii Antiarrhythmic Agent

A Quarter of a Century Later: What is Dofetilide’s Clinical Role Today?

2018 ◽  
Vol 24 (1) ◽  
pp. 3-10 ◽  
Author(s):  
Deborah L. Wolbrette ◽  
Sarah Hussain ◽  
Ilir Maraj ◽  
Gerald V. Naccarelli
Keyword(s):  
Atrial Fibrillation ◽  
Atrial Flutter ◽  
Real World ◽  
Antiarrhythmic Agent ◽  
Good Choice ◽  
Drug Trials ◽  
Efficacy And Safety ◽  
Class Iii ◽  
Clinical Role ◽  
Class Iii Antiarrhythmic Agent

Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post–myocardial infarction patients and those with heart failure. This is a review of postmarket data, including real-world efficacy and safety in a variety of populations. Dofetilide has been used off-label with success in patients with paroxysmal atrial fibrillation and atrial flutter, as well as atrial tachycardia and ventricular tachycardia. The real-world acute conversion rate of atrial fibrillation and atrial flutter is higher than that reported in clinical trials. Dofetilide has an acceptable safety profile when initiated (or reloaded) under hospital monitoring and dosed according to creatinine clearance. Dofetilide is well tolerated and a good choice for patients with acceptable renal function and a normal QT interval, especially if atrioventricular nodal blockade needs to be avoided.

Effects of a novel class III antiarrhythmic agent, CPUY11018, on rat atrial fibrillation

2010 ◽  
Vol 71 (5) ◽  
pp. 303-312 ◽  
Author(s):  
Xiang Guo ◽  
Chun-Lin Chen ◽  
Qian Yang ◽  
Yue-Miao Yin ◽  
Qi-Dong You ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Antiarrhythmic Agent ◽  
Class Iii ◽  
Class Iii Antiarrhythmic Agent

scholarly journals Amiodarone-induced vortex keratopathy at a low maintenance dose

2020 ◽  
Vol 17 (2) ◽  
pp. 170-172
Author(s):  
Deepti Mahajan ◽  
Anil Verma ◽  
Rajesh Sharma
Keyword(s):  
Atrial Fibrillation ◽  
Side Effect ◽  
Maintenance Dose ◽  
Antiarrhythmic Agent ◽  
Common Side Effect ◽  
Class Iii ◽  
Deposition Pattern ◽  
Short Term ◽  
Class Iii Antiarrhythmic Agent ◽  
Length Of Therapy

Vortex keratopathy is a common side effect of amiodarone, which is a class III antiarrhythmic agent. We describe a 50-year-old man who developed vortex keratopahy with amiodarone 200 mg BD for atrial fibrillation since two years. The daily (400 mg/day) and cumulative dose (100 g) combined with the length of therapy is associated with the toxicity. Toxic effects may also be observed at lower maintenance doses, as observed in this patient. This case indicates that multi-organ toxicity due to amiodarone may develop even with short-term use and a low maintenance dose. Having been off the medication for two months, it is expected that the deposition pattern will diminish, as is the case for the vast majority of patients.

Sign in / Sign up

Export Citation Format

Share Document